Literature DB >> 14729395

Tachykinins and tachykinin receptors: a growing family.

Jocelyn N Pennefather1, Alessandro Lecci, M Luz Candenas, Eva Patak, Francisco M Pinto, Carlo Alberto Maggi.   

Abstract

The peptides of the tachykinin family are widely distributed within the mammalian peripheral and central nervous systems and play a well-recognized role as excitatory neurotransmitters. Currently, the concept that tachykinins act exclusively as neuropeptides is being challenged, since the best known members of the family, substance P, neurokinin A and neurokinin B, are also present in non-neuronal cells and in non-innervated tissues. Moreover, the recently cloned mammalian tachykinins hemokinin-1 and endokinins are primarily expressed in non-neuronal cells, suggesting a widespread distribution and important role for these peptides as intercellular signaling molecules. The biological actions of tachykinins are mediated through three types of receptors denoted NK(1), NK(2) and NK(3) that belong to the family of G protein-coupled receptors. The identification of additional tachykinins has reopened the debate of whether more tachykinin receptors exist. In this review, we summarize the current knowledge of tachykinins and their receptors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14729395     DOI: 10.1016/j.lfs.2003.09.039

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  109 in total

Review 1.  Tachykinins and excitotoxicity in cerebellar granule cells.

Authors:  Cinzia Severini; Cristina Zona
Journal:  Cerebellum       Date:  2006       Impact factor: 3.847

Review 2.  Neurokinin-1 receptor: functional significance in the immune system in reference to selected infections and inflammation.

Authors:  Steven D Douglas; Susan E Leeman
Journal:  Ann N Y Acad Sci       Date:  2010-11-22       Impact factor: 5.691

3.  Contractile properties of the pig bladder mucosa in response to neurokinin A: a role for myofibroblasts?

Authors:  P Sadananda; R Chess-Williams; E Burcher
Journal:  Br J Pharmacol       Date:  2008-02-11       Impact factor: 8.739

4.  Evidence for mediation of nociception by injection of the NK-3 receptor agonist, senktide, into the dorsal periaqueductal gray of rats.

Authors:  Gabriel S Bassi; Ana C Broiz; Margarete Z Gomes; Marcus L Brandão
Journal:  Psychopharmacology (Berl)       Date:  2008-12-18       Impact factor: 4.530

Review 5.  The significance of substance P in physiological and malignant haematopoiesis.

Authors:  Michal Nowicki; Danuta Ostalska-Nowicka; Beata Kondraciuk; Bogdan Miskowiak
Journal:  J Clin Pathol       Date:  2006-12-15       Impact factor: 3.411

Review 6.  Substance P in heart failure: the good and the bad.

Authors:  Heather M Dehlin; Scott P Levick
Journal:  Int J Cardiol       Date:  2013-11-12       Impact factor: 4.164

7.  Mutational analysis of TAC3 and TACR3 genes in patients with idiopathic central pubertal disorders.

Authors:  Cintia Tusset; Sekoni D Noel; Ericka B Trarbach; Letícia F G Silveira; Alexander A L Jorge; Vinicius N Brito; Priscila Cukier; Stephanie B Seminara; Berenice B de Mendonça; Ursula B Kaiser; Ana Claudia Latronico
Journal:  Arq Bras Endocrinol Metabol       Date:  2012-12

Review 8.  Neurokinin receptors in drug and alcohol addiction.

Authors:  Jesse R Schank
Journal:  Brain Res       Date:  2020-02-15       Impact factor: 3.252

Review 9.  The emerging role of substance P/neurokinin-1 receptor signaling pathways in growth and development of tumor cells.

Authors:  Hossein Javid; Fariba Mohammadi; Elnaz Zahiri; Seyed Isaac Hashemy
Journal:  J Physiol Biochem       Date:  2019-08-01       Impact factor: 4.158

10.  Frequent promoter hypermethylation of tachykinin-1 and tachykinin receptor type 1 is a potential biomarker for head and neck cancer.

Authors:  Kiyoshi Misawa; Takeharu Kanazawa; Yuki Misawa; Atsushi Imai; Takayuki Uehara; Daiki Mochizuki; Shiori Endo; Goro Takahashi; Hiroyuki Mineta
Journal:  J Cancer Res Clin Oncol       Date:  2013-02-19       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.